Pharmacologic prevention of vascular access stenosis.
Vascular access dysfunction continues to result in substantial morbidity for chronic hemodialysis patients. Pharmacologic and molecular biologic approaches to prevention of vascular access dysfunction, if clinically successful, will be cost effective and improve quality of life for chronic dialysis patients. This review summarizes currently available information and future prospects in pharmacologic and molecular biologic approaches to preventing vascular access stenosis.
Himmelfarb
J
J
Division of Nephrology, Maine Medical Center, Portland 04102, USA. himmej@mail.mmc.org
D000818:Animals; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001241:Aspirin / Q000494:pharmacology; D001808:Blood Vessels / Q000528:radiation effects; D002408:Catheters, Indwelling / Q000009:adverse effects*; D003251:Constriction, Pathologic / Q000517:prevention & control; D004176:Dipyridamole / Q000494:pharmacology; D015316:Genetic Therapy; D006801:Humans; D006435:Renal Dialysis / Q000009:adverse effects*
D004176:Dipyridamole; D001241:Aspirin